Abstract
摘要
相似文献
1
[Adjuvant chemotherapy of gastric cancer].
Klin Khir. 1995(5):38-41.
2
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
Cancer Chemother Pharmacol. 2011 Jul;68(1):37-43. doi: 10.1007/s00280-010-1424-8. Epub 2010 Sep 7.
3
[Association of cancer and non-Hodgkin's lymphoma of the stomach].
Klin Khir. 1996(1):53.
4
Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
Breast J. 2007 Jul-Aug;13(4):431-2. doi: 10.1111/j.1524-4741.2007.00459.x.
5
Dose-dense paclitaxel-containing adjuvant therapy for breast cancer.
Oncology (Williston Park). 1998 Jan;12(1 Suppl 1):16-8.
6
[Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Strahlenther Onkol. 2002 Jan;178(1):54-5.
7
A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Clin Breast Cancer. 2009 Aug;9(3):161-5. doi: 10.3816/CBC.2009.n.026.
8
Patients' concerns about clinical trials in Japan.
Lancet. 1999 Mar 20;353(9157):1019-20. doi: 10.1016/S0140-6736(05)70735-2.
9
[Drug therapy for inoperable gastric cancer: current possibilities and perspectives of development].
Vopr Onkol. 2007;53(4):383-92.
10
Chemotherapy in alimentary tract malignomas.
Hepatogastroenterology. 1981 Oct;28(5):276-83.
Zotero 插件